👤 Xinmei Shen

12 articles tracked

About this journalist

Articles
12
2026-08-25 – 2026-11-03
Claims per article
4
42 extracted in total
Hedged claims
19%
corpus average 9%
Typical length
875
characters
Writes for South China Morning Post.
Hedged claims are ones written with attribution or uncertainty (“reportedly”, “according to”). A higher rate is not a fault: it is often careful sourcing. How these are measured.

What they cover

Technology
42%
Economy/Business
25%
Health
25%
Politics
8%
Most-tagged topics
ChinaChineseHong KongFDAHong Kong’sAkesoAnew LabsArriVent

Leaning

Not enough articles to place this byline.
1 scored article; a leaning average needs at least 8 before it says more about the writer than about which stories they happened to be assigned. Their outlet averages -0.09 (centre).

More from this journalist

Ordered by how many newsrooms covered the same event.
2026-09-18 · South China Morning Post · Economy/Business
From US Fed rates to China’s global export share: 4 figures shaping markets
21 outlets covered this event
2026-11-03 · South China Morning Post · Economy/Business
Tokenised gold bar to advance Hong Kong’s ambitions as digital, metal trading hub
no other outlet in the corpus covered this
2026-11-02 · South China Morning Post · Economy/Business
How Hong Kong’s fintech strategy is progressing – and where growth still lags
no other outlet in the corpus covered this
2026-10-28 · South China Morning Post · Health
Chinese drug sector’s stature grows at major cancer conference
no other outlet in the corpus covered this
2026-10-12 · South China Morning Post · Technology
Former HSBC executive launches wealth platform powered by team of AI agents
no other outlet in the corpus covered this
2026-10-07 · South China Morning Post · Health
US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
no other outlet in the corpus covered this

What they said would happen

2026-09-23 · South China Morning Post
Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
🔮 Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts speculative
2026-09-26 · South China Morning Post
China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
🔮 Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion. assertive
Forward-looking sentences extracted from their articles, oldest first. Nothing here checks whether any of it turned out to be right.
💬Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

🕘History 🎫Support